The strategic goal is to reach a leading position in Europe by entering not only into novel Women’s Healthcare areas with unmet need, but also by providing medicines to support healthcare professionals and patients in making treatment decisions that are right for patients.
Through our original research and by pursuing partnering opportunities, such as acquiring innovative products or late-stage projects, our offerings in Women’s Health are expanding. Our portfolio includes hormone replacement therapy; heavy menstrual bleeding and contraception; emergency contraception; fertility; uterine fibroids; osteoporosis and topical local anaesthesia.
